Internal medicine Oncology

News

06 Sep 2021
A synthetic CDK4/6 inhibitor exerts antitumor effects by forcing RB1 tumor-suppressor into an active status, but its single administration is not sufficiently effective. We find its combinatorial administration with an IKKβ inhibitor is significantly more effective in hepatocellular carcinoma treatment. Also, blockage of the IKK-NF-κB or AKT pathway enhances its effects on RB1-intact K-Ras mutated lung and colon cancers. CDK4/6 inhibitors have potential to treat various RB1-intact cancers when combined with an appropriate kinase inhibitor.
12 Feb 2021
In a study published in Nature Communications, cancer researchers at Kanazawa University identify mechanisms by which malignant tumor cells extend their toxicity to distinct cell types and in turn help them spread.
24 Jan 2021
Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however.
26 Mar 2020
In a recent study published in Autophagy, researchers at Kanazawa University show how abnormalities in a gene called TPR can lead to pediatric brain cancer
Image Name
23 Nov 2018
Tests show an association between how aggressive a tumour is and the levels of sugar and inflammatory proteins in the blood.

Events

Sorry, nothing coming up for this discipline

Researchers

Sorry, nothing coming up for this discipline